Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XMYPL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DB-1311
|
|||||
| Synonyms |
BNT324; DB 1311; DB-1311; DB1311
Click to Show/Hide
|
|||||
| Organization |
Duality Biologics; BioNTech SE
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
P1021
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Maleimide tetrapeptide-based cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
